title: Combined modality therapy for stage II and stage III pancreatic carcinoma.
abstract: OBJECTIVE
  To study the outcome achieved with three-drug chemotherapy and split-course external-beam radiotherapy as a treatment for unresectable stage II and III pancreatic carcinoma.
  
  
  METHODS
  Radiotherapy was given in three cycles of 2 Gy/d on days 1 to 5 and 8 to 12 (total dose, 54 Gy) concurrently with fluorouracil (FU) 1,000 mg/m2/d by continuous infusion for 4.5 days, streptozocin (STZ) 300 mg/m2 on days 1, 2, and 3 and cisplatin (P) 100 mg/m2 on day 3 of each every-28-day cycle. Subsequent treatment consisted of leucovorin (LV) 200 mg/m2 and FU 600 to 1,000 mg/m2 every 14 days.
  
  
  RESULTS
  The median survival time for the 35 patients was 15 months and 26% of patients were alive at 24 months. Fifteen patients (42.8%) had objective responses to therapy. Six (17%) had a complete response (CR). Three of nine patients with partial responses (PRs) achieved a radiographic CR within the next 3 months. Nine patients underwent attempts at surgical resection: five were resected (median survival time, 31 months; range, 12.8 to 44.7+), two had no residual disease found at complete resection, and three others also had a complete resection. Of four others who could not be resected, three underwent intraoperative radiotherapy and one had occult metastatic disease. Of primary tumors, 91% did not produce either back pain or local gastrointestinal complications for 2 years. The rates of severe side effects were stomatitis 15%, anemia 14%, granulocytopenia 6%, and thrombocytopenia 6%.
  
  
  CONCLUSIONS
  Palliation and survival compare favorably with other series, including many surgical series. The response findings encourage studies of both unresectable and (as neoadjuvant therapy) resectable tumors.
authors.affiliation: Section of Hematology/Oncology, West Virginia University Health Sciences Center, Charleston, USA.
authors.forename: A G
authors.initials: AG
authors.lastname: Kamthan
authors.forename: J C
authors.initials: JC
authors.lastname: Morris
authors.forename: J
authors.initials: J
authors.lastname: Dalton
authors.forename: J P
authors.initials: JP
authors.lastname: Mandeli
authors.forename: M R
authors.initials: MR
authors.lastname: Chesser
authors.forename: D
authors.initials: D
authors.lastname: Leben
authors.forename: A
authors.initials: A
authors.lastname: Cooperman
authors.forename: H W
authors.initials: HW
authors.lastname: Bruckner
mesh_terms: D000230:Adenocarcinoma / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D010166:Palliative Care; D010190:Pancreatic Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D011879:Radiotherapy Dosage; D013311:Streptozocin / Q000008:administration & dosage; D015996:Survival Rate
chemical_list: D013311:Streptozocin; D002945:Cisplatin; D002955:Leucovorin; D005472:Fluorouracil